Clinical trials across the GLP-1 receptor agonist class consistently show an average resting heart rate increase of 1 to 4 beats per minute
By addressing these two factors, semaglutide may help tackle the root causes of these symptoms
This is where the right combination of rewards, recognition, and gentle competition can turn a routine spin or hand into a memorable story, adding dimension to every return visit
In the UK, from early 2024 to early 2025, approximately 1.6 million adults in England, Wales, and Scotland used GLP-1 class drugs for weight loss, including semaglutide drugs like 'Wegovy' and 'Ozempic', or tirzepatide drugs like 'Mounjaro'
doi: 10.1124/jpet.108.149211
The portal makes it easy to log these symptoms, giving your medical team the information they need to fine-tune your treatment plan